• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
MDGL

MDGL

Madrigal Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD488.15

+35.29 (+7.79%)

Rating:C

Company Profile

CEO

William J. Sibold

IPO Date

2007-02-06

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$450.61

Prev. Close

$452.86

Day Low

$445.20

Day High

$490.00

52W Low

$271.96

52W High

$615.00

Market Cap

$11.25B

Volume

0.26M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

35.8%

Avg Negative

10.9%

Avg Neutral

53.3%

News Feed

Here's Why Madrigal (MDGL) is Poised for a Turnaround After Losing 14.9% in 4 Weeks

Zacks Investment Research·7/27/2021·↓ negative

Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study

GlobeNewsWire·7/13/2021·↑ positive

Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom

GlobeNewsWire·6/30/2021·↑ positive

Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial MAESTRO-NAFLD-1 at The International Liver Congress™ 2021

GlobeNewsWire·6/25/2021·↑ positive

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

GlobeNewsWire·6/8/2021·↑ positive

Madrigal Pharmaceuticals to Participate in UBS Global Healthcare Virtual Conference

GlobeNewsWire·5/21/2021·↑ positive

Alex Howarth Joins Madrigal Pharmaceuticals as Chief Financial Officer

GlobeNewsWire·5/18/2021·↑ positive

Madrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and Highlights

GlobeNewsWire·5/6/2021·↑ positive

Madrigal Pharmaceuticals: Leading The NASH Innovation

Seeking Alpha·5/5/2021·↑ positive

Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights

GlobeNewsWire·2/25/2021·↑ positive